Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Stage not disclosed · ActiveModality: active immunotherapy
Target pTau (phosphorylated Tau)
Status note Described as a clinical product candidate; FDA Fast Track designation. The filing states no per-asset phase, indication, or target.
ACI-24.060
Stage not disclosed · ActiveModality: active immunotherapy
Target Abeta (amyloid-beta)
Indications
Amyloid Plaque(Phase 2)
Beta-Amyloid(Phase 2)
DSAD(Phase 2)
Status note Described as a clinical product candidate; FDA Fast Track designation. The filing states no per-asset phase, indication, or target.
ACI-7104.056
Stage not disclosed · ActiveModality: active immunotherapy
Target alpha-synuclein
Indications
Parkinson's disease (PD)(Stage not disclosed)
Status note Described as a clinically-validated active immunotherapy candidate targeting alpha-synuclein for Parkinson's disease, acquired via the 2021 Affiris portfolio purchase. The filing states no per-asset phase.
ACI-19764
Stage not disclosed · ActiveModality: small molecule
Target NLRP3
Indications
Obesity(Phase 1)
Type 2 Diabetes Mellitus (T2DM)(Phase 1)
Status note Described as an NLRP3 inhibitor small molecule drug program, retained after the September 2025 restructuring. The filing states no per-asset phase or indication.
Morphomer Tau
Preclinical · ActiveModality: small molecule
Target tau
Status note Described as a small molecule drug program retained after the September 2025 restructuring; no clinical data stated.
Morphomer-a-syn
Preclinical · ActiveModality: small molecule
Target alpha-synuclein
Status note Described as a small molecule drug program retained after the September 2025 restructuring; no clinical data stated.
PI-2620
Stage not disclosed · ActiveModality: PET tracer diagnostic
Target tau
Status note Described as a Tau-PET tracer clinical product candidate; FDA Fast Track designation. No per-asset phase stated.
ACI-12589
Stage not disclosed · ActiveModality: PET tracer diagnostic
Target alpha-synuclein
Status note Described as an alpha-synuclein PET tracer clinical product candidate. No per-asset phase stated.
ACI-15916
Stage not disclosed · ActiveModality: PET tracer diagnostic
Target alpha-synuclein
Status note Described as an alpha-synuclein PET tracer clinical product candidate. No per-asset phase stated.
ACI-19626
Stage not disclosed · ActiveModality: PET tracer diagnostic
Target TDP-43
Status note Described as a TDP-43-PET tracer clinical product candidate. No per-asset phase stated.
Per-asset detail extracted from the 20-F filed 2026-03-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Parkinson's Disease (PD); Multiple System Atrophy (MSA); Dementia With Lewy Bodies (DLB)
—
Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.